Suppr超能文献

Abl 激酶的结构与动态调节。

Structure and dynamic regulation of Abl kinases.

机构信息

Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15219, USA.

出版信息

J Biol Chem. 2013 Feb 22;288(8):5443-50. doi: 10.1074/jbc.R112.438382. Epub 2013 Jan 11.

Abstract

The c-abl proto-oncogene encodes a unique protein-tyrosine kinase (Abl) distinct from c-Src, c-Fes, and other cytoplasmic tyrosine kinases. In normal cells, Abl plays prominent roles in cellular responses to genotoxic stress as well as in the regulation of the actin cytoskeleton. Abl is also well known in the context of Bcr-Abl, the oncogenic fusion protein characteristic of chronic myelogenous leukemia. Selective inhibitors of Bcr-Abl, of which imatinib is the prototype, have had a tremendous impact on clinical outcomes in chronic myelogenous leukemia and revolutionized the field of targeted cancer therapy. In this minireview, we focus on the structural organization and dynamics of Abl kinases and how these features influence inhibitor sensitivity.

摘要

c-abl 原癌基因编码一种独特的蛋白酪氨酸激酶(Abl),与 c-Src、c-Fes 和其他细胞质酪氨酸激酶不同。在正常细胞中,Abl 在细胞对遗传毒性应激的反应以及调节肌动蛋白细胞骨架方面发挥着重要作用。在 Bcr-Abl 中,Abl 也很有名,Bcr-Abl 是慢性髓性白血病的致癌融合蛋白。Bcr-Abl 的选择性抑制剂,其中伊马替尼是原型,对慢性髓性白血病的临床结果产生了巨大影响,并彻底改变了靶向癌症治疗领域。在这篇综述中,我们重点介绍 Abl 激酶的结构组织和动力学,以及这些特征如何影响抑制剂的敏感性。

相似文献

1
Structure and dynamic regulation of Abl kinases.
J Biol Chem. 2013 Feb 22;288(8):5443-50. doi: 10.1074/jbc.R112.438382. Epub 2013 Jan 11.
2
Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
Curr Opin Oncol. 2002 Nov;14(6):616-20. doi: 10.1097/00001622-200211000-00005.
4
Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Biomed Pharmacother. 2013 Mar;67(2):157-63. doi: 10.1016/j.biopha.2012.10.017. Epub 2012 Nov 19.
6
Mechanisms of transformation by the BCR/ABL oncogene.
Int J Hematol. 2001 Apr;73(3):278-91. doi: 10.1007/BF02981952.
7
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Blood. 2004 Apr 15;103(8):3167-74. doi: 10.1182/blood-2003-04-1271. Epub 2003 Dec 11.
10
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Blood. 2007 Apr 15;109(8):3470-8. doi: 10.1182/blood-2006-02-005579. Epub 2007 Jan 3.

引用本文的文献

1
KinaseFusionDB: an integrative knowledge of kinase fusion proteins in multi-scales.
Brief Bioinform. 2025 May 1;26(3). doi: 10.1093/bib/bbaf259.
2
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia.
Arch Pharm (Weinheim). 2025 May;358(5):e70005. doi: 10.1002/ardp.70005.
3
Tracking protein kinase targeting advances: integrating QSAR into machine learning for kinase-targeted drug discovery.
Future Sci OA. 2025 Dec;11(1):2483631. doi: 10.1080/20565623.2025.2483631. Epub 2025 Apr 4.
5
An SH3-binding allosteric modulator stabilizes the global conformation of the AML-associated Src-family kinase, Hck.
J Biol Chem. 2025 Jan;301(1):108088. doi: 10.1016/j.jbc.2024.108088. Epub 2024 Dec 13.
6
Global hinge sites of proteins as target sites for drug binding.
Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2414333121. doi: 10.1073/pnas.2414333121. Epub 2024 Nov 25.
7
New ABL1 Kinase Domain Mutations in BCR::ABL1-Positive Acute Lymphoblastic Leukemia.
Cancer Med. 2024 Oct;13(20):e70317. doi: 10.1002/cam4.70317.
8
The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance.
Chem Sci. 2024 Jul 13;15(33):13130-13147. doi: 10.1039/d4sc01088d. eCollection 2024 Aug 22.
9
Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance.
Cancers (Basel). 2024 Aug 2;16(15):2754. doi: 10.3390/cancers16152754.
10
Exploring the conformational landscape of protein kinases.
Curr Opin Struct Biol. 2024 Oct;88:102890. doi: 10.1016/j.sbi.2024.102890. Epub 2024 Jul 22.

本文引用的文献

1
Partial cooperative unfolding in proteins as observed by hydrogen exchange mass spectrometry.
Int Rev Phys Chem. 2013 Jan 1;32(1):96-127. doi: 10.1080/0144235X.2012.751175.
3
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
Cell. 2011 Oct 14;147(2):306-19. doi: 10.1016/j.cell.2011.08.046.
6
Allosteric interactions between the myristate- and ATP-site of the Abl kinase.
PLoS One. 2011 Jan 10;6(1):e15929. doi: 10.1371/journal.pone.0015929.
7
ABL tyrosine kinases: evolution of function, regulation, and specificity.
Sci Signal. 2010 Sep 14;3(139):re6. doi: 10.1126/scisignal.3139re6.
8
Multidomain assembled states of Hck tyrosine kinase in solution.
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15757-62. doi: 10.1073/pnas.1004569107. Epub 2010 Aug 23.
9
Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.
J Biol Chem. 2010 Jul 9;285(28):21446-57. doi: 10.1074/jbc.M109.090043. Epub 2010 May 7.
10
Hydrogen exchange mass spectrometry: what is it and what can it tell us?
Anal Bioanal Chem. 2010 Jun;397(3):967-72. doi: 10.1007/s00216-010-3556-4. Epub 2010 Mar 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验